Company Overview
EdiGene Inc. is a clinical-stage company focusing on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs.
Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T, and LEAPERTM-based in vivo RNA base editing.
-
2015
Founded
-
4
Locations
-
4
R&D platforms
-
270+
employees
Company Overview
EdiGene Inc. is a clinical-stage company focusing on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs.
Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T, and LEAPERTM-based in vivo RNA base editing.
Our History
Expansion and Rapid Growth
Translation and Development
Concept and Research
January: Entered into strategic R&D collaboration with Haihe Laboratory of Cell Ecosystem
February: LEAPER™ 2.0, an updated version of the RNA base editing technology published on Nature Biotechnology by Scientific Founder Wensheng Wei’s lab at Peking University
February: Worldwide non-exclusive license agreement with Arbor Biotechnologies
March: Worldwide license agreement with Boston Children's Hospital
April: Entered a research collaboration with Peking University Cancer Hospital
January: IND application approved by China NMPA
September: First patient enrolled in the Phase I multi-center clinical trial of ET-01
November:Entered research collaboration with the University of Wisconsin-Madison and Peking Union Medical College Hospital respectively
December: Poster presentation of latest research on hematopoietic stem cell at ASH Annual Meeting and Exposition
May: Oral presentation of RNA base editing program data at ASGCT Annual Meeting
May: Collaboration with Immunochina to jointly develop allogeneic CAR-T Therapy for Cancer
October: IND application for its CRISPR/Cas9 gene-editing hematopoietic stem cell therapy ET-01 in β-thalassemia accepted for review by China NMPA
January: Clinical-scale manufacturing capability established
July: RNA base editing technology LEAPER™ first published on Nature Biotechnology by Scientific Founder Wensheng Wei’s lab at Peking University
December: Poster presentation of ET-01 data at ASH Annual Meeting and Exposition
November: Established GMP-level gene-editing application center
April: First gene-editing therapy platform established
November: First collaboration with clinician
May: Company founded
